Trial Profile
Phase I/II study of the combination of arsenic trioxide with ascorbic acid and high-dose melphalan for patients with multiple myeloma.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Arsenic trioxide (Primary) ; Melphalan
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 13 May 2008 New trial record.